Related Experiment Video
Updated: Aug 11, 2026
04:23
A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease
Published on: April 28, 2019
Viral Dynamic Model-Informed Dose Selection of Mosnodenvir Prophylaxis against DENV-3 in a Controlled Human Infection
Nele Goeyvaerts1, Xavier Woot de Trixhe1, Martine Neyens1
1Johnson & Johnson, Beerse, Belgium.
Clinical Pharmacology and Therapeutics
|August 10, 2026
Summary
Mosnodenvir effectively prevents Dengue virus type 3 (DENV-3) infection in a controlled human infection model. This antiviral drug
Area of Science:
- Virology
- Pharmacology
- Infectious Diseases
Background:
- Dengue virus (DENV) poses a significant global health risk.
- Mosnodenvir (JNJ-64281802) is an investigational antiviral agent targeting pan-serotype DENV replication.
Purpose of the Study:
- To evaluate mosnodenvir's antiviral activity, safety, and pharmacokinetics as prophylaxis against DENV-3.
- To develop a combined population pharmacokinetic (PopPK) and viral dynamic model (VDM) for dose selection.
Main Methods:
- A Phase IIa controlled human infection model (CHIM) study (NCT05048875) was conducted.
- A two-compartment PopPK model utilized data from Phase I and IIa studies.
- A VDM incorporated an immune response compartment and a sigmoid Emax model for antiviral effect.
Main Results:
- The PopPK model estimated mosnodenvir exposure across different doses.
- The VDM accurately described DENV-3 RNA profiles and the drug's effect on virion production.
- Simulations supported daily and weekly mosnodenvir dosing regimens.
Conclusions:
- The combined PopPK/VDM approach successfully informed mosnodenvir dose selection.
- The study characterized the pharmacokinetic-antiviral activity relationship for mosnodenvir.
- Findings support mosnodenvir's development as a prophylactic treatment for dengue.
